PO49 Presentation Time: 10:00 AM: Prevalence of QTc Prolongation in Prostate Cancer Patients Undergoing Brachytherapy

Abstract

<h3>Purpose</h3> QTc has been associated not only with a higher risk of Torsade de Pointes (TdP), sudden cardiac arrest but also with general cardiac mortality, including cardiovascular and coronary death. We examined the prevalence of prolonged QTc interval in prostate cancer patients undergoing brachytherapy in general and in patients with more aggressive cancers who may be exposed to ADT and compared them to patients who underwent prostatectomy. <h3>Materials and Methods</h3> We randomly selected 1094 patients treated with either low-dose rate (LDR) or high-dose rate (HDR) brachytherapy between August 2010 and February 2022 from our internal database. All patients had an ECG as part of the preoperative work-up. The QTc was automatically calculated using the Bazett formula. Excluded were patients with left or complete bundle branch block, ventricular extrasystoles, atrial fibrillation, presence of a pacemaker or a QRS ≥ 120 ms. .As primary outcome, a QTc ≥450ms was considered abnormal. Chi-square or Fisher's exact test, when appropriate was used to compare groups. Pearson correlation coefficient and binary multivariable regression analysis was used to evaluate correlations between QTc and clinical values. <h3>Results</h3> A total of 6.2% (n=68) had a QTc ≥450ms. Patients with a Cancer of the Prostate Risk Assessment (CAPRA) high risk disease (score 6-10) were significantly more likely to have a QTc ≥450ms than patients with low-or intermediate risk (9.7% vs. 5.5%, p=0.039). QTc as a continuous variable correlated weakly with the neutrophil count (r=0.13, p<0.001), age (r=0.08, p=0.009) and inversely with testosterone (r=-0.17, p=0.002). On binary multivariable regression analysis including neutrophils, testosterone and age, only testosterone [nmol/L] was predictive of a QTc ≥450ms, OR 0.9, 95% CI 0.82-0.98, p=0.02. We then compared the patients treated with brachytherapy to 178 patients who underwent prostatectomy. The latter had a non-significantly smaller portion of patient with a QTc ≥450ms: 4.5% vs. 6.2%, p=0.5. <h3>Conclusions</h3> Our data show that about 10% of patients with high-risk prostate cancer are at increased risk of TdP. Treating physicians should be aware of this and monitor the QTc during ADT to possible decrease cardiac mortality in these patients who require ADT. The correlation between increasing age, neutrophil count and low testosterone with QTc prolongation links inflammation and hypogonadism.